Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607008 | 0.86 | PIK3CA (0.33) | EGLN2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3600429 | 0.85 | — | — | |
| SCHEMBL3606283 | 0.82 | PIK3CA (0.32) | EGLN2PIK3CAPIK3CBPIK3CG | |
| Trifluoroacetic Acid SCHEMBL3610302 | 0.78 | — | — | |
| SCHEMBL5076231 | 0.75 | GSK3B (0.38) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3608386 | 0.74 | PIK3CA (0.33) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL10270747 | 0.74 | GSK3B (0.53) | EGLN2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3603974 | 0.74 | EGLN2 (0.35) | EGLN2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL4417355 | 0.72 | GSK3B (0.59) | PIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL18813497 | 0.72 | GSK3B (0.59) | PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| EP-2137188-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Pharma AG (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-2137188-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | EGLN2 1710/4885PIK3CA 405/4885PIK3CB 788/4885 |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | THPO, TYMP, TPMT | EGLN2 2683/4885PIK3CA 223/4885PIK3CB 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.